Though multiple clinical trials have shown that angiotensin-converting enzyme inhibitors (ACEI) (Lewis et al., 1993) and Angiotensin II (Ang II) type 1 receptor (AT1R) blockades (ARB) (Brenner et al., 2001) attenuate DN, these effects were limited and were unable to halt the progression of DN into end-stage organ failure (Zhang et al., 2011). Here, AGTR1 is linked to liver dysplastic nodule.